Melatonin binding site MT3 is QR2: State of the art;Le récepteur MT3: Où en sommes-nous?

Journal de la Societe de Biologie

Volumn 201, Issue 1, 2007, Pages 97-103

  Boutin, Jean A ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CONFERENCE PAPER; HAMSTER; HUMAN; MOLECULAR GENETICS; MOLECULAR WEIGHT; PHYSIOLOGY; PINEAL BODY; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CRICETINAE; HUMANS; MELATONIN; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; NAD(P)H DEHYDROGENASE (QUINONE); PINEAL GLAND; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTORS, MELATONIN; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

MUS;

EID: 34548451699     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio:2007011     Document Type: Conference Paper

References (30)

1. 2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 2003, 367, 553-561.
2. Beck-Andre M., Wiesenburg I., Schaeren-Wiemers N., Andre E., Missbach M., Saurat J. H. & Carlberg C., Pineal gland melatonin binds and activates an orpan of the nuclear receptor subfamily. J. Biol. Chem., 1994, 269, 28531-28534.
3. Bian K., Ke Y., Kamisaki Y. & Murad F., Proteomic modification by nitric oxide., J. Pharmacol. Sci., 2006, 101, 271-279.
4. Boutin J. A., Tyrosine protein kinase inhibition and cancer. Int. J. Biochem., 1994, 26, 1203-1226.
5. Boutin J. A., Tyrosine protein kinase assays. J. Chromatog., 1996, 684, 179-199.
6. Boutin J. A., Audinot V., Ferry G. & Delagrange P., Molecular tools to study melatonin pathways and actions. Trends in Pharmacol. Sci., 2005a, 26, 412-419.
7. Boutin J. A., Chatelain-Egger F., Vella F., Delagrange P. & Ferry G., Quinone reductase 2 substrate specificity and inhibition pharmacology. Chem. Biol. Inter., 2005b, 151, 213-228.
8. Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh T.C., Wu J. M. & Zhang Z., Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004, 43, 11417-11426.
9. Delagrange P., Boutin J. A., Therapeutic potential of melatonin ligands. Chronobiol. Int., 2006, 23, 413-418.
10. Ferry G., Loynel A., Kucharczyk N., Bertin S., Rodriguez M., Delagrange P., Galizzi J. P., Jacoby E., Volland J. P., Lesieur D., Renard P., Canet E., Fauchère J. L. & Boutin J. A., Substrate specificity and inhibition studies of human serotonin N-acetyltransferase. J. Biol. Chem., 2000, 275, 8794-8805.
11. Foster C. E., Bianchet M. A., Talalay P., Zhao Q. & Amzel L. M., Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry, 1999, 38, 9881-9886.
12. Gow A. J., Farkouh C. R., Munson D. A., Posencheg M. A. & Ischidopoulos H., Biological significance of nitric oxide-mediated protein modifications., Am. J. Phyiol. Lung Cell. Mol. Physiol., 2004, 287, L262-268.
13. Grimaldi S., Lanciano P., Bertrand P., Blasco F. & Guigliarelli B., Evidence for an EPR-detectable semiquinone intermediate stabilized in the membrane-bound subunit NarI of nitrate reductase A (NarGHI) from Escherichia coli. Biochemistry, 2005, 44, 1300-1308.
14. Knox R. J., Jenkins T. C., Hobbs S. M., Chen S., Melton R. G. & Burke P. J., Bioactivation of 5-(azirin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res., 2000, 60, 4179-4186.
15. Lagneux C., Joyeux M., Demenge P., Ribuot C. & Godin-Ribuot D., Protective effects of melatonin against ischemia-reperfusion-injury in the isolated rat heart. Life sci., 2000, 66, 503-509.
16. Long D. J., Iskander K., Gaikwad A., Arin M., Roop D. R., Knox R., Barrios R. & Jaiswal A. K., Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J. Biol. Chem., 2002, 277, 46131-46139.
17. 2. Biochem. Pharmacol., 2004a, 67, 667-677.
18. 3. FEBS Lett., 2004b, 578, 116-120.
19. 3 binding site as the NRH:quinone oxidoreductase 2 catalytic site. Biochem. Pharmacol., 2005, 71, 74-88.
20. Molinari E. J., North P. C., Dubocovich M. L., 2-[125I]iodo-5- methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites. Eur. J. Pharmacol., 1996, 301, 159-168.
21. 3 as the Quinone reductase 2. J. Biol. Chem., 2000, 275, 31311-31317.
22. 3/QR2. Biochem. Pharmacol., 2001, 61, 1369-1379.
23. Paul P., Lahaye C., Delagrange P., Nicolas J. P., Canet E. & Boutin J. A., Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J. Pharmacol. Exp. Ther., 1999, 290, 334-340.
24. Pickering D. S. & Niles L. P., Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus. Eur. J. Pharmacol., 1990, 175, 71-77.
25. 3 receptor. Br. J. Pharmacol., 2003, 138, 831-836.
26. Reiter R. J., Melchiorri D., Sewerynek E., Poeggeler B., Barlow-Walden L., Chuang J., Ortiz G. G. & Acuna-Castroviejo D., A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res., 1995, 18, 1-11.
27. Reppert S. M., Weaver D. R. & Ebisawa T., Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron, 1994, 13, 1177-1185.
28. Reppert S. M., Godson C., Mahle C. D., Weaver D. R., Slaugenhaupt S. A. & Gusella J. F., Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc. Natl. Acad. Sci. USA, 1995, 92, 8734-8738.
29. Steinhilber D., Brungs M., Werz O., Wiesenberg I., Danielsson C., Kahlen J. P., Nayeri S., Schräder M. & Carlberg C., The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J. Biol. Chem., 1995, 270, 7037-7040.
30. Vella F., Ferry G., Delagrange P. & Boutin J. A., NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol., 2005, 71, 1-12.